Langdown M L, Holness M J, Sugden M C
Department of Diabetes and Metabolic Medicine, Division of General and Developmental Medicine, St Bartholomew's and the Royal London School of Medicine and Dentistry, Queen Mary, University of London, London, UK.
J Endocrinol. 2001 Apr;169(1):11-22. doi: 10.1677/joe.0.1690011.
In the rat, dexamethasone treatment during late pregnancy leads to intrauterine growth retardation and is used as a model of early programming of adult onset disease. The present study investigated whether pre-natal dexamethasone treatment modifies cardiac glucose transporter (GLUT) protein expression in adulthood and identified signalling pathways involved in the response. Dexamethasone (100 microg/kg body wt per day) administered via an osmotic pump to pregnant rats (day 15 to day 21; term=22 to 23 days) reduced fetal weight at day 21 and caused hypertension, hyperinsulinaemia and elevated corticosterone levels in the adult (24-week-old) male offspring. Cardiac GLUT1 protein expression was selectively up-regulated (2.5-fold; P<0.001), in the absence of altered cardiac GLUT4 protein expression, in adult male offspring of dexamethasone-treated dams. Maternal dexamethasone treatment did not influence cardiac GLUT1 protein expression during fetal or early post-natal life. We examined potential regulatory signalling proteins that might mediate up-regulation of cardiac GLUT1 protein expression in adulthood. We observed marked (2.2-fold; P<0.01) activation of Akt/protein kinase B (PKB), together with modest activation of the anti-apoptotic protein kinase C (PKC) isoforms PKC alpha (88%, P<0.05) and PKC epsilon (56%, P<0.05) in hearts of the early-growth-retarded male offspring. These effects were, however, observed in conjunction with up-regulation of cardiac protein expression of PKC beta(1) (191%, P<0.01), PKC beta(2) (49%, P<0.05) and PKC delta (35%; P<0.01), effects that may have adverse consequences. Maternal dexamethasone treatment was without effect on cardiac extracellular signal-related kinase (ERK) 1 or ERK2 activity in adulthood. In conclusion, our data demonstrate an effect of maternal dexamethasone treatment to up-regulate cardiac GLUT1 protein expression in early-growth-retarded, hypertensive, hyperinsulinaemic adult male offspring, an effect observed in conjunction with activation of Akt/PKB.
在大鼠中,孕期晚期给予地塞米松治疗会导致子宫内生长迟缓,并被用作成年发病疾病早期编程的模型。本研究调查了产前地塞米松治疗是否会改变成年期心脏葡萄糖转运蛋白(GLUT)的蛋白表达,并确定了参与该反应的信号通路。通过渗透泵给怀孕大鼠(第15天至第21天;孕期为22至23天)注射地塞米松(每天100微克/千克体重),可使第21天的胎儿体重减轻,并导致成年(24周龄)雄性后代出现高血压、高胰岛素血症和皮质酮水平升高。在接受地塞米松治疗的母鼠的成年雄性后代中,心脏GLUT1蛋白表达选择性上调(2.5倍;P<0.001),而心脏GLUT4蛋白表达未改变。母体地塞米松治疗在胎儿期或出生后早期对心脏GLUT1蛋白表达没有影响。我们检查了可能介导成年期心脏GLUT1蛋白表达上调的潜在调节信号蛋白。我们观察到早期生长迟缓的雄性后代心脏中Akt/蛋白激酶B(PKB)明显激活(2.2倍;P<0.01),同时抗凋亡蛋白激酶C(PKC)亚型PKCα(88%,P<0.05)和PKCε(56%,P<0.05)有适度激活。然而,这些效应与心脏中PKCβ(1)(191%,P<0.01)、PKCβ(2)(49%,P<0.05)和PKCδ(35%;P<0.01)的蛋白表达上调同时出现,这些效应可能会产生不良后果。母体地塞米松治疗对成年期心脏细胞外信号调节激酶(ERK)1或ERK2活性没有影响。总之,我们的数据表明,母体地塞米松治疗对早期生长迟缓、高血压、高胰岛素血症的成年雄性后代心脏GLUT1蛋白表达有上调作用,这种作用与Akt/PKB的激活同时出现。